Evaluation of Predictive Factors for Successful Intravitreal Dexamethasone in Pseudophakic Cystoid Macular Edema
Table 2
Number
Dexamethasone injection time duration after symptoms (days)
Effective phaco-emulsification time (sec)
Pretreatment central foveal thickness (μm)
Δ logMAR (pretreatment/posttreatment)
Δ central fovea thickness (pretreatment/posttreatment)
Adjuvant bevanizumab injection (y/n)
Diabetes mellitus (y/n)
Arterial hypertension (y/n)
Follow-up time after Dex implant treatment (days)
Ocular side effects
Systemic adverse side effects
1
106
2.17
384
0
−14
y
y
Y
706
None
None
2
496
n/a
767
−0.2
−207
y
n
Y
196
None
None
3
256
3.39
356
0.1
29
n
n
N
242
None
None
4
197
1.96
550
0.1
24
n
n
Y
147
None
None
5
136
0.13
510
−0.2
−249
n
n
N
64
None
None
6
136
0.04
310
−0.2
−5
y
y
N
34
None
None
7
108
4.71
522
−0.2
−237
n
n
N
81
None
None
8
104
3.22
323
−0.1
−38
n
y
N
265
None
None
9
675
1.73
489
−0.1
−213
n
n
Y
71
None
None
10
240
1.28
436
−0.4
−190
n
n
N
60
None
None
11
129
0
764
−0.5
−485
n
n
N
76
None
None
12
239
0
568
−0.1
−179
n
n
Y
60
None
None
13
77
0.88
582
−0.2
−205
n
n
Y
67
None
None
14
52
0
553
−0.8
−256
y
y
n
13
None
None
15
295
1.66
325
0.6
104
y
n
y
798
None
None
16
95
1.88
646
−0.8
−430
n
n
n
256
None
None
17
62
0.66
573
−0.4
−320
n
n
n
61
None
None
18
64
n/a
311
−0.2
−33
n
n
y
77
None
None
19
240
n/a
462
−0.1
−189
n
n
n
61
None
None
The table summarizes outcome measurements, treatment procedures, selected systemic disease, and safety findings of all 19 patients included in this study. All patients who experienced a CFT reduction more than 200 μm have been marked bold in this table.
